Hikma Pharmaceuticals/£HIK

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical company headquartered in London, United Kingdom. It specializes in the development, manufacturing, and marketing of a broad portfolio of branded and non-branded generic and in-licensed pharmaceutical products. The company operates across three main segments: Injectables, Generics, and Branded, serving hospitals, pharmacies, and wholesalers. Hikma was founded in 1978 in Amman, Jordan, and has since expanded its operations globally, maintaining a significant presence in the Middle East and North Africa, the United States, and Europe. Its strategic positioning is supported by its extensive manufacturing capabilities and a strong commitment to quality and regulatory compliance.

Ticker

£HIK
Sector

Primary listing

LSE

Employees

9,500

HIK Metrics

BasicAdvanced
£3.7B
13.48
£1.23
0.60
£0.60
3.62%

What the Analysts think about HIK

Analyst ratings (Buy, Hold, Sell) for Hikma Pharmaceuticals stock.

Bulls say / Bears say

Hikma is racing to launch generic versions of Novo Nordisk’s Ozempic and Wegovy once patents begin expiring from 2026, targeting a global weight-loss drug market valued at $80–140 billion and poised for high demand for lower-cost generics (FT.com).
Hikma’s injectables segment has treated over 800,000 patients with its technology converting IV medications into subcutaneous injections, underscoring strong partnership momentum and bolstering its injectables pipeline across oncology and autoimmune therapies (Bloomberg).
FT notes Hikma is the second-largest drugmaker by sales in the Middle East and North Africa, providing a stable revenue base and significant growth prospects in emerging markets where it faces limited competition (FT.com).
Hikma agreed to pay $50 million to settle a class action alleging it colluded to delay its generic Xyrem approval for the narcolepsy drug Xyrem, highlighting material litigation risk and potential further liabilities (Reuters).
The FDA’s declaration that the national shortage of branded Ozempic and Wegovy is over removes a key catalyst for generic copycats like Hikma, potentially slowing initial uptake of its planned semaglutide generics (Bloomberg).
The U.S. government’s new most-favored-nation drug pricing policy threatens to cap prices for branded drugs without generic competition, which could compress margins in Hikma’s Branded segment in key markets (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

HIK Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

HIK Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £HIK

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

Sept18
Hikma Pharmaceuticals
DividendPayment
£0.265842Per share
FAQs